Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20471851 | 1.00 | HSD17B10 (0.34) | HSD17B10CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL25280480 | 0.93 | HSD17B10 (0.40) | HSD17B10ALDH1A1SMN1; SMN2MEN1LMNA | |
| SCHEMBL20471741 | 0.93 | HSD17B10 (0.40) | HSD17B10ALDH1A1SMN1; SMN2MEN1LMNA | |
| SCHEMBL20471739 | 0.93 | HSD17B10 (0.40) | HSD17B10ALDH1A1SMN1; SMN2MEN1LMNA | |
| SCHEMBL820844 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL375388 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL375387 | 0.85 | ALDH1A1 (0.36) | ALDH1A1MEN1LMNATSHRKMT2A | |
| SCHEMBL7874264 | 0.85 | CHRM2 (0.36) | HSD17B10CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL817959 | 0.85 | CHRM2 (0.36) | HSD17B10CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL144260 | 0.85 | CHRM2 (0.36) | HSD17B10CHRM2CHRM1CHRM3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110191882-B | Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them | 株式会社大熊制药 | 2022-09-13 | — | — | CN | disclosed |
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2021-04-20 | — | — | US | disclosed |
| WO-2018147626-A1 | NOVEL HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2018-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10981917-B2 | Heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | RNASE1, AARS1, DHPS | HSD17B10 659/4885CHRM2 4871/4885CHRM1 4823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.